PROTHENA CORPORATION PUBLIC LIMITED COMPANY Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 544.91 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 277.07K shares, a 366.64% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 267.84K shares, a 76.15% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 1.26M shares, a 370.71% increase year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 23.91K shares, a 73.48% decline year-over-year.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 1.49M shares, a 276.26% increase from fiscal 2024.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 397.29K shares, a 1633.70% increase from fiscal 2023.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 22.92K shares.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 0.00 shares, a 100.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 277.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 544.91K shares 10-Q · filed 2026-08-06 | 1.80M shares derived: sum of 3 quarters · filed 2026-08-06 | 1.83M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 267.84K shares 10-Q · filed 2026-05-07 | 1.53M shares derived: sum of 2 quarters · filed 2026-05-07 | 1.55M shares derived: sum of 3 quarters · filed 2026-05-07 | 1.61M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 1.26M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | 1.28M shares derived: sum of 2 quarters · filed 2026-02-27 | 1.34M shares derived: sum of 3 quarters · filed 2026-02-27 | 1.49M shares 10-K · filed 2026-02-27 |
| 2025-09-30 | 23.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 83.28K shares derived: sum of 2 quarters · filed 2025-11-06 | 235.33K shares 10-Q · filed 2025-11-06 | 502.92K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 59.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | 211.43K shares 10-Q · filed 2025-08-04 | 479.01K shares derived: sum of 3 quarters · filed 2025-08-04 | 569.14K shares derived: sum of 4 quarters · filed 2025-08-04 |
| 2025-03-31 | 152.05K shares 10-Q · filed 2025-05-08 | 419.64K shares derived: sum of 2 quarters · filed 2025-05-08 | 509.76K shares derived: sum of 3 quarters · filed 2025-05-08 | 538.97K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 267.58K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 357.71K shares derived: sum of 2 quarters · filed 2025-02-27 | 386.92K shares derived: sum of 3 quarters · filed 2025-02-27 | 397.29K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 90.13K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 119.33K shares derived: sum of 2 quarters · filed 2024-11-12 | 129.71K shares 10-Q · filed 2024-11-12 | 152.63K shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 29.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 39.58K shares 10-Q · filed 2024-08-08 | 62.50K shares derived: sum of 3 quarters · filed 2024-08-08 | 62.50K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 10.38K shares 10-Q · filed 2024-05-08 | 33.29K shares derived: sum of 2 quarters · filed 2024-05-08 | 33.29K shares derived: sum of 3 quarters · filed 2024-05-08 | 33.29K shares derived: sum of 4 quarters · filed 2024-05-08 |
| 2023-12-31 | 22.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 22.92K shares derived: sum of 2 quarters · filed 2024-02-22 | 22.92K shares derived: sum of 3 quarters · filed 2024-02-22 | 22.92K shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-02 | 0.00 shares 10-Q · filed 2023-11-02 | 0.00 shares derived: sum of 4 quarters · filed 2023-11-02 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 0.00 shares 10-Q · filed 2023-08-03 | 0.00 shares derived: sum of 3 quarters · filed 2023-08-03 | 0.00 shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-04 | 0.00 shares derived: sum of 2 quarters · filed 2023-05-04 | 0.00 shares derived: sum of 3 quarters · filed 2023-05-04 | 0.00 shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | 0.00 shares derived: sum of 2 quarters · filed 2023-02-28 | 0.00 shares derived: sum of 3 quarters · filed 2023-02-28 | 0.00 shares 10-K · filed 2023-02-28 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 0.00 shares derived: sum of 2 quarters · filed 2022-11-03 | 0.00 shares 10-Q · filed 2022-11-03 | 0.00 shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 0.00 shares 10-Q · filed 2022-08-08 | 0.00 shares derived: sum of 3 quarters · filed 2022-08-08 | 0.00 shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-05 | 0.00 shares derived: sum of 2 quarters · filed 2022-05-05 | 0.00 shares derived: sum of 3 quarters · filed 2022-05-05 | 0.00 shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | 0.00 shares derived: sum of 2 quarters · filed 2022-02-25 | 0.00 shares derived: sum of 3 quarters · filed 2022-02-25 | 2.00M shares 10-K · filed 2022-02-25 |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 0.00 shares derived: sum of 2 quarters · filed 2021-11-04 | 2.00M shares 10-Q · filed 2021-11-04 | 2.28M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | 2.00M shares 10-Q · filed 2021-08-05 | 2.28M shares derived: sum of 3 quarters · filed 2021-08-05 | 2.28M shares derived: sum of 4 quarters · filed 2021-08-05 |
| 2021-03-31 | 2.00M shares 10-Q · filed 2021-05-11 | 2.28M shares derived: sum of 2 quarters · filed 2021-05-11 | 2.28M shares derived: sum of 3 quarters · filed 2021-05-11 | 2.28M shares derived: sum of 4 quarters · filed 2021-05-11 |
| 2020-12-31 | 273.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 273.86K shares derived: sum of 2 quarters · filed 2021-02-26 | 277.56K shares derived: sum of 3 quarters · filed 2021-02-26 | 295.19K shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 3.71K shares derived: sum of 2 quarters · filed 2020-11-04 | 21.34K shares 10-Q · filed 2020-11-04 | |
| 2020-06-30 | 3.71K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 21.34K shares 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | 17.63K shares 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | 490.22K shares 10-K · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |